BioNTech, Roche’s pancreatic cancer treatment bodes well for future: Nature
Half of the trial participants had developed T cells that can potentially recognise cancerous cells and stop them from re-emerging
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Genentech
FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic…
Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high…
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive…
Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional…
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
The approval is primarily based on the results of two Phase III studies, VIALE-A and VIALE-C
Roche’s Genentech gets US FDA approval for Gavreto (pralsetinib)
The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer
US FDA approves Enspryng from Genentech for neuromyelitis optica spectrum disorder
In two randomised controlled Phase III clinical trials, SAkuraStar and SAkuraSky studies, Enspryng demonstrated robust and…
US DOJ permits six drug makers to share info about COVID-19 MAb treatments to expedite production
The approval granted through a business review letter from the Justice Department's antitrust division, however, has not allowed…